Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline HCl Cream 1.0% for Persistent Erythema in Rosacea
NCT02132117Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AGN-199201 in rosacea (2 arms), sponsored by Allergan. Primary endpoint: Percentage of Participants With at Least a 2-Grade Improvement From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA). Started Jun 2014; status: completed.
02
Drugs
AGN-199201
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT02132117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132117.